Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Relative Bioavailability Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PD-0332991

First Posted Date: 2012-05-21

Last Posted Date: 2012-11-12

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01602887

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids

Phase 4

Completed

Conditions: Inflammation

Interventions: Drug: CsA+MMF+CS
Drug: CsA+Rapamune+CS

First Posted Date: 2012-05-18

Last Posted Date: 2018-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 245

Registration Number: NCT01601821

Locations: 🇮🇷
Modarres Hospital, Tehran, Iran, Islamic Republic of
🇮🇷
Shariati Hospital, Tehran, Iran, Islamic Republic of
🇮🇷
Taleqani Hospital, Tehran, Iran, Islamic Republic of

and more 1 locations

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340

Phase 1

Completed

Conditions: PAIN

Interventions: Drug: PF-06273340 or Placebo

First Posted Date: 2012-05-18

Last Posted Date: 2012-07-04

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT01601834

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Tofacitinib Bioequivalence Study Comparing Tablets And Capsules

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tofacitinib 5 mg
Drug: tofacitinib 10 mg

First Posted Date: 2012-05-16

Last Posted Date: 2012-07-10

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT01599377

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Phase 3

Completed

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Interventions: Drug: Ceftazidime - Avibactam ( CAZ-AVI)
Drug: Doripenem

First Posted Date: 2012-05-16

Last Posted Date: 2017-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 641

Registration Number: NCT01599806

Locations: 🇺🇦
Research Site, Zaporizhzhya, Ukraine

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Crizotinib (Xalkori)

First Posted Date: 2012-05-14

Last Posted Date: 2019-09-13

Lead Sponsor: Pfizer

Target Recruit Count: 2029

Registration Number: NCT01597258

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: enzalutamide
Drug: anastrozole
Drug: exemestane
Drug: fulvestrant

First Posted Date: 2012-05-11

Last Posted Date: 2019-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT01597193

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Tennessee Oncology, PLLC., Nashville, Tennessee, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 10 locations

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Phase 3

Completed

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Interventions: Drug: Ceftazidime - Avibactam ( CAZ-AVI)
Drug: Doripenem

First Posted Date: 2012-05-10

Last Posted Date: 2017-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 598

Registration Number: NCT01595438

Locations: 🇺🇦
Research Site, Zaporizhzhya, Ukraine

Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo

Phase 1

Completed

Conditions: Narcotic Abuse
Opioid-related Disorders
Analgesia
Chronic Pain

Interventions: Drug: Placebo
Drug: EMBEDA - morphine sulfate/ naltrexone hydrochloride
Drug: morphine sulfate CR crushed.

First Posted Date: 2012-05-10

Last Posted Date: 2012-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 33

Registration Number: NCT01595867

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Phase 2

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: PBO
Drug: 200mg PF-04950615 (RN316)
Drug: PF-04950615
Drug: 300mg PF-04950615 (RN316)

First Posted Date: 2012-05-07

Last Posted Date: 2017-12-05

Lead Sponsor: Pfizer

Target Recruit Count: 354

Registration Number: NCT01592240

Locations: 🇺🇸
Southwest Heart Group, Tucson, Arizona, United States
🇺🇸
Universal Biopharma Research Institute Inc. - Alta Family Health Clinic, Dinuba, California, United States
🇺🇸
Clinical Trials Research, Lincoln, California, United States

and more 67 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy